Rachel F. Tyndale mainly focuses on Nicotine, Pharmacology, CYP2A6, Cotinine and Smoking cessation. Nicotine is a subfield of Internal medicine that Rachel F. Tyndale studies. Her Pharmacology study incorporates themes from CYP2B6, Microsome, Addiction and Cytochrome P450.
The study incorporates disciplines such as Oral administration, Pharmacogenetics, Genotype and Genetic variation in addition to CYP2A6. Her studies deal with areas such as Metabolite, Urine and Carcinogen as well as Cotinine. The Smoking cessation study combines topics in areas such as Anesthesia, Placebo and Single-nucleotide polymorphism.
Rachel F. Tyndale mainly investigates Nicotine, Pharmacology, CYP2A6, Internal medicine and Smoking cessation. Cotinine is the focus of her Nicotine research. Her studies examine the connections between Pharmacology and genetics, as well as such issues in Cytochrome P450, with regards to Neurotoxicity.
Her CYP2A6 research incorporates themes from Nicotine metabolism, Genetic variation, Allele and Genotype. Her study looks at the relationship between Internal medicine and topics such as Endocrinology, which overlap with Endocannabinoid system and Alkaloid. Her Smoking cessation research incorporates elements of Randomized controlled trial and Abstinence.
Her scientific interests lie mostly in Nicotine, Internal medicine, Smoking cessation, Endocrinology and Cotinine. Her research in Nicotine intersects with topics in Metabolite, Craving, CYP2A6 and Physiology. Her research integrates issues of Pharmacokinetics, Pharmacology, Glucuronidation, Urine and Biomarker in her study of Metabolite.
Rachel F. Tyndale interconnects Pharmacogenetics, Genome-wide association study, Allele and Genetic association in the investigation of issues within CYP2A6. Rachel F. Tyndale has included themes like Nicotine patch and Randomized controlled trial in her Smoking cessation study. Rachel F. Tyndale combines subjects such as Gastroenterology, Buprenorphine, Opioid and Methadone with her study of Cotinine.
Nicotine, Internal medicine, Smoking cessation, Endocrinology and CYP2A6 are her primary areas of study. Rachel F. Tyndale specializes in Nicotine, namely Cotinine. Her research in the fields of Nucleus accumbens overlaps with other disciplines such as Efavirenz.
Her study in Smoking cessation is interdisciplinary in nature, drawing from both Young adult, Abstinence and Physiology. Her studies in Endocrinology integrate themes in fields like Tropomyosin receptor kinase B and Endocannabinoid system. Her CYP2A6 research is multidisciplinary, relying on both Metabolite, Pharmacogenetics, Genome-wide association study and Allele.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines on nicotine dose selection for in vivo research
Shannon G. Matta;David J. Balfour;Neal L. Benowitz;R. Thomas Boyd.
Psychopharmacology (2007)
Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.
T Aoyama;S Yamano;D J Waxman;D P Lapenson.
Journal of Biological Chemistry (1989)
Nicotine metabolism defect reduces smoking
Michael L. Pianezza;Edward M. Sellers;Rachel F. Tyndale.
Nature (1998)
A Major Role for CYP2A6 in Nicotine C-Oxidation by Human Liver Microsomes
E S Messina;R F Tyndale;E M Sellers.
Journal of Pharmacology and Experimental Therapeutics (1997)
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Delia Dempsey;Delia Dempsey;Delia Dempsey;Piotr Tutka;Piotr Tutka;Piotr Tutka;Peyton Jacob;Peyton Jacob;Peyton Jacob;Faith Allen;Faith Allen;Faith Allen.
Clinical Pharmacology & Therapeutics (2004)
Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Kelly E. Caudle;Teri E. Klein;James M. Hoffman;Daniel J. Muller.
Current Drug Metabolism (2014)
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Kerri A Schoedel;Ewa B Hoffmann;Yushu Rao;Edward M Sellers.
Pharmacogenetics (2004)
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes
James D McKay;Rayjean J Hung;Younghun Han;Xuchen Zong.
Nature Genetics (2017)
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
Viba Malaiyandi;Edward M. Sellers;Rachel F. Tyndale.
Clinical Pharmacology & Therapeutics (2005)
Duplications and Defects in the CYP2A6 Gene: Identification, Genotyping, and In Vivo Effects on Smoking
Yushu Rao;Ewa Hoffmann;Mohammad Zia;Laurent Bodin.
Molecular Pharmacology (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of California, San Francisco
University of Toronto
University of Southern California
Centre for Addiction and Mental Health
Stanford University
Centre for Addiction and Mental Health
Centre for Addiction and Mental Health
Rutgers, The State University of New Jersey
University at Buffalo, State University of New York
University of Helsinki
University of Oulu
Georgia Institute of Technology
King's College London
University of Illinois at Chicago
University of Science and Technology Beijing
Harbin Institute of Technology
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
Japan Women's University
Chinese University of Hong Kong
University of Washington
University at Albany, State University of New York
University of Iowa
Utah State University
Arizona State University
Monash University